Search for Fatty Acid Synthase

From:Jeff Silverman

Heather- One approach I have used to track down antibodies or other
methodological needs is to run a Medline (Pub Med) search and read the
abstracts to see what researchers are doing what you want to do. If the
details are not in the Materials and Methods section of their paper, you can
contact the lead author perhaps for info. A Pub Med search for fatty acid
synthase and antibody yields these leads:

Cancer Res. 56: 1189-1193 (1996)
Inhibition of fatty acid synthesis delays disease progression in a xenograft
model of ovarian cancer.
Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore,
Maryland 21287, USA.

One of the key limiting factors in the treatment of advanced stage human
epithelial malignancies is the lack of selective molecular targets for
antineoplastic therapy. A substantial subset of human ovarian, endometrial,
breast, colorectal, and prostatic cancers exhibit increased endogenous fatty
acid biosynthesis and overexpress certain enzymes in the pathway. Cell lines
derived from these tumors use endogenously synthesized fatty acids for
cellular functions, whereas normal cells and tissues appear to utilize
dietary lipids preferentially. We have previously shown that the difference
in fatty acid biosynthesis between cancer and normal cells is an exploitable
target for metabolic inhibitors in vitro. Here, we report observations in
vivo using the i.p. model of the multiply drug-resistant OVCAR-3 human
ovarian carcinoma in nude mice which demonstrate that: (a) fatty acid
synthase overexpression in OVCAR-3 is comparable to levels in primary human
tumors assessed by immunohistochemistry; (b) fatty acid synthetic activity
of OVCAR-3 is comparably elevated in vitro and in vivo and is 4 to >20-fold
higher than normal murine tissues; (c) treatment with the specific fatty
acid synthase inhibitor, cerulenin, markedly reduces tumor cell fatty acid
biosynthesis in vivo; (d) fatty acid synthase inhibition produces regression
of established ascites tumor; and (e) treatment with cerulenin causes
reduction in ascites incidence, delay in onset of ascites, and significantly
increased survival (P<0.04).

Another paper published in full online yielded this reference that they used
(first the online paper, then the paper you want to get to get details of
the antibody).

Malonyl-Coenzyme-A Is a Potential Mediator of Cytotoxicity Induced by
Fatty-Acid Synthase Inhibition in Human Breast Cancer Cells and Xenografts1
Ellen S. Pizer, Jagan Thupari, Wan Fang Han, Michael L. Pinn, Francis J.
Chrest, Gojeb L. Frehywot, Craig A. Townsend and Francis P. Kuhajda2
Department of Pathology, The Johns Hopkins University School of Medicine,
Baltimore, Maryland 21224 [E. S. P., J. T., W. F. H., M. L. P., F. P. K.];
Research Resources Branch/Flow Cytometry Unit, Gerontology Research Center,
National Institute on Aging, Baltimore, Maryland 21224 [F. J. C.]; and
Department of Chemistry, The Johns Hopkins University, Baltimore, Maryland
21218 [G. L. F., C. A. T.]
M and M
FAS Immunohistochemistry.
Immunohistochemistry for FAS was performed on the MCF-7 xenografts using a
mouse monoclonal anti-FAS antibody (1) at 1:2000 on the DAKO Immunostainer
using the LSAB2 detection kit.

The refernece they used to to FAS immuno:
1.  Alo P. L., Visca P., Marci A., Mangoni A., Botti C., Di Tondo U.
Expression of fatty acid synthase (FAS) as a predictor of recurrence in
stage I breast carcinoma patients. Cancer (Phila.), 77: 474-482,

Hope this helps
Jeff Silverman HT HTL QIHC ASCP
Southside Hospital (There is no peptolab except m email address :o)
Bay Shore NY USA

<< Previous Message | Next Message >>